Seattle — Dec. 18, 2025 — Fred Hutch Cancer Center researchers have developed a new tool that enables anyone to immediately assess their colorectal cancer risk online. Called MyGeneRisk, the free, web-based calculator allows users to input basic health information, including lifestyle habits and genetic data, to estimate their risk.
With colorectal cancer on the rise and now the third most common cancer and the second leading cause of cancer death in the U.S., researchers were interested in creating a tool that could help users initiate conversations with their healthcare providers about their risk and explore early interventions or lifestyle changes to reduce their risk.
“Our aim in creating this tool was to help people engage with information on colorectal cancer and empower them understand their risk in an interactive way,” said Ulrike “Riki” Peters, PhD, MPH, genetic epidemiologist in the Fred Hutch Public Health Sciences Division and Fred Hutch 40th Anniversary Endowed Chair.
To assess their risk, users can upload raw genetic data from direct-to-consumer DNA testing services and answer questions about lifestyle, such as diet, exercise and smoking habits. Users without genetic data can simply complete the lifestyle portion of the questionnaire. The tool then generates a report based on the user’s genetic and lifestyle information, providing a personalized risk assessment for colorectal cancer and educating users about actions to take based on level of risk, such as lifestyle changes and screenings.
The tool determines a user’s risk using a polygenic risk score, which combines the effects of over 1 million genetic variants associated with colorectal cancer risk into a single score.
”We collaborated with researchers around the world, bringing together the largest genetic dataset for colorectal cancer to date, including over 100,000 participants with colorectal cancer and 150,000 control participants,” said Li Hsu, PhD, a biostatistician in Fred Hutch’s Public Health Sciences Division. ”Our risk prediction model integrates that robust genetic data with lifestyle and environmental factors using machine-learning approaches.”
To ensure data safety and security, MyGeneRisk intakes user data to create a personalized risk score, allows the user to download the result, then deletes the user’s genetic and lifestyle information. The tool does not ask the user’s name, email address or phone number, and does not store or share the data provided.
“Data security was one of our top considerations when developing MyGeneRisk. To maximize protection of individual information, once the calculation of a user’s risk score is completed, the tool immediately deletes the information and does not store the results,” said Robert Steinfelder, PhD, a member of Dr. Peters’ team who developed the tool’s underlying architecture.
With MyGeneRisk now launched for colorectal cancer, the research team plans to expand the tool for other cancers and incorporate rare genetic mutations to further enhance risk prediction.
”Our team is eager to explore how we can continue to build upon this tremendous work and help empower more people to know their cancer risk and the steps they can take to improve their health,” said Peters.
Visit the site at mygenerisk-colon.fredhutch.org.
###
This tool is for educational purposes only and does not replace medical advice or diagnosis from a health care provider. Read full Disclaimer and Terms of Service.
###
Media Contact:
Kat Wynn
kwynn@fredhutch.org
Fred Hutchinson Cancer Center
Fred Hutch Cancer Center unites individualized care and advanced research to provide the latest cancer treatment options while accelerating discoveries that prevent, treat and cure cancer and infectious diseases worldwide.
Based in Seattle, Fred Hutch is an independent, nonprofit organization and the only National Cancer Institute-designated cancer center in Washington. We have earned a global reputation for our track record of discoveries in cancer, infectious disease and basic research, including important advances in bone marrow transplantation, immunotherapy, HIV/AIDS prevention and COVID-19 vaccines. Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy and related services. Fred Hutch also serves as UW Medicine’s cancer program.